Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Patent
1998-07-02
2000-06-20
Reamer, James H.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
A61K 31135
Patent
active
060778717
ABSTRACT:
Compositions of matter comprising droloxifene or a pharmaceutically acceptable salt thereof and a cyclodextrin. Preferred cyclodextrins are SBECD and HPBCD. The composition can comprise a dry mixture, a dry inclusion complex or an aqueous solution. The citrate salt of droloxifene is preferred.
REFERENCES:
patent: 5047431 (1991-09-01), Schickaneder et al.
patent: 5254594 (1993-10-01), Niikura et al.
patent: 5550164 (1996-08-01), Fontana
F. Hirayama, et al., J. Pharamaceutical Sciences, vol. 81, No. 8, Aug. 1992, pp. 817-822, "Prominent Inculsion Effect of Dimethyl-.beta.-cyclodextrin on Photoisometrization of the Thromboxane Synthetase Inhibitor (E-4-(1-Imidazoylmenthyl)cinnamic Acid".
P. Bortolus, et al., J. Phys. Chem, 1987, 91, pp. 5046-5050, CIS .sup..rarw. .sub..fwdarw. Trans Photoisomerization of Azobenzene-Cyclodextrin Inclusion Complexes.
T. Loftsson, et al., Pharmaceutical Sciences, Oct. 1996, vol. 85, No. 10, pp. 1017-1025, "Pharmaceutical Applications of Cyclodextrins. 1. Drug Solubilization and Stabilization".
E. Pop, et al., PHarmaceutical Research, vol. 8, No. 8, 1991, pp. 1044-1049, "Solubilization and Stabilization of Benzylpenicillin Chemical Delivery System by 2-Hydroxpropyl-.beta.-cyclodextrin".
B. Gorecka, et al, International Journal of Pharmaceutics 125(1995) pp. 55-61, "Effect of SBE4-.beta. -CD, a sulfobutyl ether .beta.-cyclodextrin, on the stability and solubility of O.sup.6 -benzylguanine (NSC-637037) in aqueous solutions".
M. Brewster, et al., Pharmaceutical Research, vol. 8, No. 6, 1991, pp. 792-795, "Use of 2-Hydroxypropyl-.beta.-cyclodextrin as a Solubilizing and Stabilizing Excipient for Protein Drugs".
F. Hirayama, et al., Duchene, D., Ed.; Editions de Sante: Paris 1987; Chapter 4, pp. 131-172, "Cyclodextrins and their Industrial Uses".
J. Szejtli, Pharmaceutical Technology, Aug. 1991, pp. 24-38, "Cyclodextrins in Drug Formulations: Part II".
G. Duveneck, et al., J. Phys. Chem, 1989, 93, pp. 7166-7170, "Picosecond Laser Studies on Photochemical Reactions in Restricted Environments: The Photoisomerization of trans-Stilbene Complexed to Cyclodextrins".
H. Helm, et al., European Journal of Pharmaceutical Sciences 3 (1995) pp. 195-201, "Complexation of dihydroergotamine mesylate with cyclodextrin derivatives: Solubility and stability in aqueous solution".
B.W. Muller, et al., In: Proc. 4th Int. Symp. Cyclodextrins, 369-382 (1988) "Cyclodextrin Derivatives for Solubilisation, Stabilisation, and Absorption of Drugs".
Benson Gregg C.
Olson A. Dean
Pfizer Inc.
Reamer James H.
Richardson Peter C.
LandOfFree
Droloxifene pharmaceutical compositions does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Droloxifene pharmaceutical compositions, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Droloxifene pharmaceutical compositions will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1854005